Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications

University of Michigan Rogel Cancer Center

Status: Terminated

Conditions: Multiple Chronic Conditions; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia

Treatments: Other: Communications between oncology and primary care pharmacists; Other: Patient Reported Outcome Measure (PROM); Other: Comprehensive Medication Review (CMR)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04595851

HUM00178781 (Other Identifier)

UMCC 2020.053

Details and patient eligibility

About

The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care practices (Pharmacists Coordinated care Oncology Model [PCOM]).

This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.

Enrollment: 6 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Has primary care physician
• Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), or multiple myeloma (MM)
• Initiating an OAA, either for the first time or a change from previous OAA
• Diagnosis of at least 2 chronic conditions, including at least one of the following: diabetes, hypertension, hyperlipidemia, congestive heart failure, depression/anxiety, gastroesophageal reflux disease, and/or chronic obstructive pulmonary disease
• Patients taking at least two chronic medications, including at least one medication for one of the conditions listed above.
• Willing and able to sign informed consent.

Exclusion criteria

• Cannot speak English
• Concurrent diagnosis of type 1 diabetes
• Concurrent diagnosis of human immunodeficiency virus

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Pharmacist Coordinated care Oncology Model (PCOM)

Other group

Description:

The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and primary care pharmacists.

Treatment:

Other: Patient Reported Outcome Measure (PROM)

Other: Communications between oncology and primary care pharmacists

Other: Comprehensive Medication Review (CMR)